Reata Pharmaceuticals Analysis
| RETADelisted Stock | USD 109.67 3.31 2.93% |
Reata Pharmaceuticals is overvalued with Real Value of 87.46 and Hype Value of 109.67. The main objective of Reata Pharmaceuticals delisted stock analysis is to determine its intrinsic value, which is an estimate of what Reata Pharmaceuticals is worth, separate from its market price. There are two main types of Reata Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Reata Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Reata Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
Reata |
Reata Stock Analysis Notes
About 88.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 2.62. Reata Pharmaceuticals had not issued any dividends in recent years. Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas. Reata Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 346 people. To find out more about Reata Pharmaceuticals contact Warren Huff at 972 865 2219 or learn more at https://www.reatapharma.com.Reata Pharmaceuticals Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Reata Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Reata Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Reata Pharmaceuticals is not yet fully synchronised with the market data | |
| Reata Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.22 M. Net Loss for the year was (311.9 M) with loss before overhead, payroll, taxes, and interest of (167.63 M). | |
| Reata Pharmaceuticals currently holds about 481.47 M in cash with (204.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.19. | |
| Over 88.0% of the company shares are owned by institutional investors |
Reata Pharmaceuticals Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Reata Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of November 2023 Upcoming Quarterly Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View | |
| 30th of June 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Reata Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.57 B.Reata Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Reata Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Reata Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Reata Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Michael Wortley over a year ago Disposition of 49701 shares by Michael Wortley of Reata Pharmaceuticals subject to Rule 16b-3 | ||
Michael Wortley over a year ago Sale by Michael Wortley of 807 shares of Reata Pharmaceuticals | ||
Michael Wortley over a year ago Acquisition by Michael Wortley of 4125 shares of Reata Pharmaceuticals subject to Rule 16b-3 | ||
Michael Wortley over a year ago Sale by Michael Wortley of 894 shares of Reata Pharmaceuticals | ||
Michael Wortley over a year ago Sale by Michael Wortley of 414 shares of Reata Pharmaceuticals | ||
Michael Wortley over a year ago Acquisition by Michael Wortley of 63650 shares of Reata Pharmaceuticals subject to Rule 16b-3 |
Reata Pharmaceuticals Outstanding Bonds
Reata Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Reata Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Reata bonds can be classified according to their maturity, which is the date when Reata Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| O 5625 13 OCT 32 Corp BondUS756109BP80 | View | |
| O 505 13 JAN 26 Corp BondUS756109BQ63 | View | |
| O 485 15 MAR 30 Corp BondUS756109BR47 | View | |
| O 34 15 JAN 28 Corp BondUS756109BH64 | View | |
| US756109BJ21 Corp BondUS756109BJ21 | View | |
| O 31 15 DEC 29 Corp BondUS756109BK93 | View | |
| O 285 15 DEC 32 Corp BondUS756109BL76 | View | |
| US756109BA12 Corp BondUS756109BA12 | View |
Reata Pharmaceuticals Predictive Daily Indicators
Reata Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Reata Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 0.0483 | |||
| Daily Balance Of Power | (0.59) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 112.45 | |||
| Day Typical Price | 111.52 | |||
| Market Facilitation Index | 5.57 | |||
| Price Action Indicator | (4.43) | |||
| Period Momentum Indicator | (3.31) | |||
| Relative Strength Index | 60.78 |
About Reata Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Reata Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Reata shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Reata Pharmaceuticals. By using and applying Reata Stock analysis, traders can create a robust methodology for identifying Reata entry and exit points for their positions.
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas. Reata Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 346 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Reata Pharmaceuticals to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Backtesting Now
Portfolio BacktestingAvoid under-diversification and over-optimization by backtesting your portfolios |
| All Next | Launch Module |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Reata Stock
If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |